Renaud Sabatier researcher
Sabatier, Renaud, 1981-....
Sabatier, Renaud
VIAF ID: 173485475 (Personal)
Permalink: http://viaf.org/viaf/173485475
Preferred Forms
-
100 0 _ ‡a Renaud Sabatier ‡c researcher
-
100 1 _ ‡a Sabatier, Renaud
-
100 1 _ ‡a Sabatier, Renaud ‡d 1981-...
-
100 1 _ ‡a Sabatier, Renaud, ‡d 1981-....
4xx's: Alternate Name Forms (1)
5xx's: Related Names (2)
- 510 2 _
‡a
Aix-Marseille Université
‡4
affi
‡4
https://d-nb.info/standards/elementset/gnd#affiliation
‡e
Affiliation
- 551 _ _
‡a
Marseille
‡4
ortw
‡4
https://d-nb.info/standards/elementset/gnd#placeOfActivity
Works
Title | Sources |
---|---|
Are there candidates for high-dose chemotherapy in ovarian carcinoma? |
![]() |
Are we turning to more than a first line treatment of metastatic colorectal cancer with high dose irinotecan?: A monocentric institution safety analysis of 46 patients. |
![]() |
[An "ariditary" form of ovarian cancer] |
![]() |
Axillary lymph node micrometastases decrease triple-negative early breast cancer survival. |
![]() |
Benefit of adjuvant chemotherapy with or without trastuzumab in pT1ab node-negative human epidermal growth factor receptor 2-positive breast carcinomas: results of a national multi-institutional study. |
![]() |
Carcinomatous myelitis and meningitis after a squamous cell carcinoma of the lip. |
![]() |
The CINSARC signature: prognostic and predictive of response to chemotherapy? |
![]() |
[Circulating tumor DNA assessment for gynaecological cancers management] |
![]() |
Claudin-low breast cancers: clinical, pathological, molecular and prognostic characterization |
![]() |
Could thyroid dysfunction influence outcome in sunitinib-treated metastatic renal cell carcinoma? |
![]() |
Development of parallel reaction monitoring (PRM)-based quantitative proteomics applied to HER2-Positive breast cancer |
![]() |
Down-regulation of ECRG4, a candidate tumor suppressor gene, in human breast cancer. |
![]() |
Facteurs pronostiques de l'évolution des cancers du sein triples négatifs : étude clinico-pathologique rétrospective |
![]() |
Gene expression profiling and prediction of clinical outcome in ovarian cancer. |
![]() |
Immune checkpoints inhibitors for solid tumours after allogeneic haematopoietic stem-cell transplantation: About four clinical cases. |
![]() |
Immunohistochemical subtypes predict survival in metastatic breast cancer receiving high-dose chemotherapy with autologous haematopoietic stem cell transplantation. |
![]() |
Immunohistochemical subtypes predict the clinical outcome in high-risk node-negative breast cancer patients treated with adjuvant FEC regimen: results of a single-center retrospective study. |
![]() |
Impact of Her2 and BRCA1/2 status in high-dose chemotherapy and autologous stem cells transplantation in the treatment of breast cancer: The Institut Paoli Calmettes' experience |
![]() |
Invasive ductal breast carcinoma with predominant intraductal component: Clinicopathological features and prognosis. |
![]() |
Liquid Biopsies for Ovarian Carcinoma: How Blood Tests May Improve the Clinical Management of a Deadly Disease |
![]() |
Low-grade extraskeletal osteosarcoma of the chest wall: case report and review of literature. |
![]() |
Metro : étude de phase I de chimiothérapie métronomique à visée antiangiogénique dans les néoplasies avancées de l'adulte |
![]() |
Metro1 : a phase I study of metronomic chemotherapy in adult with advanced refractory solid tumour. |
![]() ![]() |
Nivolumab in routine practice for older patients with advanced or metastatic non-small cell lung cancer |
![]() |
Ovarian cancer patients at high risk of BRCA mutation: the constitutional genetic characterization does not change prognosis. |
![]() |
Peritumoural vascular invasion: a major determinant of triple-negative breast cancer outcome. |
![]() ![]() |
Personalized medicine: present and future of breast cancer management. |
![]() |
PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer. |
![]() |
Poly(ADP-ribose) polymerase-1 mRNA expression in human breast cancer: a meta-analysis. |
![]() |
Prédire l'efficacité d'un inhibiteur d'AKT (LY2780301) dans le cancer du sein métastatique par analyse de l'ADN tumoral circulant plasmatique : étude ancillaire d'un essai de phase IB/II (TAKTIK) |
![]() |
Prognostic and predictive value of PDL1 expression in breast cancer |
![]() |
Prognostic factors for ovarian epithelial cancer in the elderly: a case-control study. |
![]() |
Prognostic impact of hormone receptor- and HER2-defined subtypes in inflammatory breast cancer treated with high-dose chemotherapy: a retrospective study. |
![]() |
Recherche d'altérations moléculaires dans les cancers du sein de sous-type basal |
![]() |
Safety and efficacy of eribulin for "real-world" older patients with metastatic breast cancer. |
![]() |
"Stealth" tumors: Breast cancer cells shun NK-cells anti-tumor immunity. |
![]() |
Stem Cells Inhibition by Bevacizumab in Combination with Neoadjuvant Chemotherapy for Breast Cancer |
![]() |
Targeted NGS, array-CGH, and patient-derived tumor xenografts for precision medicine in advanced breast cancer: a single-center prospective study |
![]() |
Targeting Deficiency in Breast Cancer: What are the Clinical Evidences and the Next Perspectives? |
![]() |
[Trastuzumab emtansine (Kadcyla(®)) approval in HER2-positive metastatic breast cancers]. |
![]() |
[Triple-negative breast cancer: histoclinical and molecular features, therapeutic management and perspectives]. |
![]() |
Value of Dynamic Contrast-enhanced and Diffusion-weighted MR Imaging in the Detection of Pathologic Complete Response in Cervical Cancer after Neoadjuvant Therapy: A Retrospective Observational Study. |
![]() |